What is Wedbush’s Forecast for ASND Q3 Earnings?

Ascendis Pharma A/S (NASDAQ:ASND) – Stock analysts at Wedbush issued their Q3 2024 earnings per share (EPS) estimates for Ascendis Pharma A/S in a report released on Monday, November 4th. Wedbush analyst Y. Zhong expects that the biotechnology company will post earnings of ($1.98) per share for the quarter. Wedbush currently has a “Strong-Buy” rating on the stock. The consensus estimate for Ascendis Pharma A/S’s current full-year earnings is ($7.24) per share. Wedbush also issued estimates for Ascendis Pharma A/S’s Q4 2024 earnings at ($1.71) EPS, FY2024 earnings at ($8.27) EPS, Q1 2025 earnings at ($1.86) EPS, Q2 2025 earnings at ($1.25) EPS, Q3 2025 earnings at ($1.01) EPS, Q4 2025 earnings at $1.25 EPS, FY2025 earnings at ($2.81) EPS, FY2026 earnings at $0.64 EPS, FY2027 earnings at $5.19 EPS and FY2028 earnings at $10.99 EPS.

Ascendis Pharma A/S (NASDAQ:ASND) last released its quarterly earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.54) by ($0.51). The firm had revenue of $38.75 million during the quarter, compared to the consensus estimate of $94.74 million.

Several other equities analysts have also commented on ASND. The Goldman Sachs Group upped their target price on Ascendis Pharma A/S from $180.00 to $200.00 and gave the company a “buy” rating in a research note on Tuesday, September 17th. Evercore ISI upped their target price on Ascendis Pharma A/S from $191.00 to $205.00 and gave the company an “outperform” rating in a research note on Tuesday, September 17th. Bank of America upped their target price on Ascendis Pharma A/S from $175.00 to $191.00 and gave the company a “buy” rating in a research note on Monday, September 23rd. StockNews.com upgraded Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research note on Thursday, September 5th. Finally, Jefferies Financial Group boosted their price target on Ascendis Pharma A/S from $174.00 to $196.00 and gave the company a “buy” rating in a research report on Tuesday, August 13th. Two analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $195.92.

Ascendis Pharma A/S Trading Down 2.2 %

Ascendis Pharma A/S stock opened at $126.55 on Thursday. The firm has a market capitalization of $7.67 billion, a P/E ratio of -13.59 and a beta of 0.66. The stock has a fifty day moving average price of $132.54 and a 200 day moving average price of $133.30. Ascendis Pharma A/S has a 52 week low of $86.54 and a 52 week high of $161.00.

Institutional Investors Weigh In On Ascendis Pharma A/S

Several institutional investors and hedge funds have recently modified their holdings of ASND. BNP Paribas Financial Markets boosted its position in shares of Ascendis Pharma A/S by 4,231.4% in the first quarter. BNP Paribas Financial Markets now owns 75,540 shares of the biotechnology company’s stock worth $11,419,000 after buying an additional 73,796 shares during the period. GSA Capital Partners LLP purchased a new position in Ascendis Pharma A/S in the first quarter valued at about $992,000. SG Americas Securities LLC purchased a new position in Ascendis Pharma A/S in the first quarter valued at about $288,000. ProShare Advisors LLC boosted its holdings in Ascendis Pharma A/S by 9.9% in the first quarter. ProShare Advisors LLC now owns 4,025 shares of the biotechnology company’s stock valued at $608,000 after purchasing an additional 361 shares during the last quarter. Finally, Westfield Capital Management Co. LP boosted its holdings in Ascendis Pharma A/S by 1.1% in the first quarter. Westfield Capital Management Co. LP now owns 4,075,214 shares of the biotechnology company’s stock valued at $616,050,000 after purchasing an additional 44,580 shares during the last quarter.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.